Mrna Cancer Therapeutics Patent Landscape Report And Forecast 2024-2032 Featuring Pfizer, Moderna, And Novartis With 650 Patents Combined

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 11, 2025 (GLOBE NEWSWIRE) -- The "mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.
The mRNA cancer therapeutics market was valued at USD 13.23 billion in 2023. It is expected to grow at a CAGR of 14.6% during the forecast period of 2024-2032 and attain a market value of USD 45 billion by 2032. The patent landscape reflects the growth, showcasing innovations in treatment protocols, manufacturing processes, and immune rejection strategies, underscoring the sector's dynamic advancements and competitive development.

The report provides a detailed analysis of the mRNA cancer therapeutics patent landscape, focusing on key elements influencing landscape dynamics. It covers jurisdictional trends, with insights into patent activity in the United States, Europe, and Asia. The report also highlights major companies shaping the field, such as Pfizer, Moderna, and Novartis, detailing their contributions and patent portfolios.

Additionally, it examines critical drivers of innovation, including advancements in mRNA stability, delivery systems, and immunogenicity. By exploring these factors, the report offers a comprehensive overview of technological progress and competitive developments in mRNA cancer therapeutics.
mRNA Cancer Therapeutics Patent Outlook

• The US has over 350 mRNA cancer therapeutics patents due to innovation and regulations. Europe has around 250 patents from collaborations and investments. Asia, mainly China and Japan, has approximately 150 patents due to progress and support.
• Key players in the patent landscape include Pfizer, Inc., with over 200 patents focusing on mRNA stability and delivery systems; Moderna, Inc., holding around 300 patents for lipid nanoparticle delivery and mRNA optimisation; and Novartis AG, with approximately 150 patents on adjuvants and scalable production techniques, driving innovation in mRNA cancer therapeutics.
• Advancements in mRNA stability, delivery systems using lipid nanoparticles and polymer-based carriers, and RNA sequence modifications with immunostimulatory adjuvants enhance immune responses against cancer cells.

mRNA Cancer Therapeutics Introduction
mRNA cancer therapeutics represent a groundbreaking approach in oncology, using messenger RNA to instruct cells to produce proteins that target and destroy cancer cells. This innovative method offers precise, personalised treatments with fewer side effects compared to traditional therapies. By leveraging the body's own cellular machinery, mRNA therapeutics can elicit strong immune responses, providing robust and adaptable cancer treatment options that hold significant promise for improving patient outcomes and advancing cancer care.

• Patent activity in mRNA cancer therapeutics is significantly driven by innovations in enhancing mRNA stability. Patents focus on chemical modifications, such as incorporating pseudouridine and 5-methylcytosine, to improve the structural integrity and longevity of mRNA. These modifications help prevent degradation and ensure sustained protein expression in cancer cells, which is crucial for maintaining therapeutic efficacy and reducing the frequency of dosing, thereby directly impacting the patent landscape.
• The development of advanced delivery systems is a major driver of patent activity in mRNA cancer therapeutics. Patents in this domain focus on lipid nanoparticles (LNPs), liposomes, and polymer-based carriers to protect mRNA and facilitate efficient cellular delivery. Innovations include targeting ligands and PEGylation to enhance delivery efficiency, minimise off-target effects, and improve the bioavailability of mRNA therapeutics. These advancements ensure precise delivery to cancer cells, boosting therapeutic effectiveness and expanding the patent landscape.
• Efforts to enhance immunogenicity are pivotal in driving patent activity in mRNA cancer therapeutics. Patents cover RNA sequence modifications, such as optimising codon usage and incorporating immunostimulatory adjuvants, to elicit stronger immune responses against cancer cells. These innovations focus on increasing protein expression and antigen presentation, improving the vaccine's efficacy. Such advancements broaden the application of mRNA cancer treatments, making them more effective and personalised, thereby contributing significantly to the expanding patent landscape.

These drivers collectively shape a dynamic and rapidly advancing patent landscape in mRNA cancer therapeutics, heralding substantial innovations and broader utilisation. Advancements in mRNA stability, delivery systems, and immunogenicity are key factors propelling this growth, ensuring the continued evolution and impact of mRNA cancer treatments in oncology.
MRNA Cancer Therapeutics Patent Segmentation Analysis
Analysis by Type

The mRNA cancer therapeutics patent landscape, segmented by type, is led by self-amplifying mRNA vaccines with over 400 patents filed and 150 currently in process, due to their enhanced efficacy, lower dosage requirements, and ability to generate stronger immune responses. Non-amplifying mRNA vaccines hold around 250 patents. Challenges include regulatory hurdles and manufacturing complexities. Despite these, future prospects are promising, driven by technological advancements and growing demand for effective, personalised cancer treatments.
Analysis by Route of Administration

The mRNA cancer therapeutics patent landscape, segmented by route of administration, is led by intravenous administration with over 300 patents filed and 100 currently in process, due to its effectiveness in delivering precise doses directly to the bloodstream. Intramuscular routes have around 200 patents. This route leads due to its established use in clinical settings and ability to ensure rapid bioavailability. Future advancements focus on improving patient compliance and minimising side effects.
Analysis by Therapeutic Area

The mRNA cancer therapeutics patent landscape, segmented by therapeutic area, is led by oncology with over 500 patents filed and 200 currently in process. Infectious diseases follow with around 300 patents. The focus on oncology is due to its potential for significant impact on patient outcomes. Future prospects, are supported by expanding research funding, collaborative efforts, and advancements in personalised medicine, promising robust growth in this sector.
mRNA Cancer Therapeutics Patent Jurisdiction Analysis
The mRNA cancer therapeutics patent landscape shows significant activity across key jurisdictions. The United States leads with over 350 patents, driven by a strong innovation ecosystem and supportive regulatory framework. Europe follows with around 250 patents, benefitting from robust collaborative networks and significant biotech investments. Asia, particularly China and Japan, accounts for approximately 150 patents, reflecting rapid advancements and substantial government support. Each region faces challenges in harmonising patent laws and navigating regulatory complexities, but ongoing efforts in international collaboration and standardisation are expected to streamline processes, fostering further innovation and growth in mRNA cancer therapeutics globally.
Key Attributes:

Report Attribute	Details
No. of Pages	200
Forecast Period	2024 - 2032
Estimated Market Value (USD) in 2024	$15.2 Billion
Forecasted Market Value (USD) by 2032	$45 Billion
Compound Annual Growth Rate	14.6%
Regions Covered	Global

Key Topics Covered:
1 Introduction
2 Executive Summary
3 Global mRNA Vaccine and Therapeutic Market Overview
3.1 Global mRNA Vaccine and Therapeutic Market Historical Value (2017-2023)
3.2 Global mRNA Vaccine and Therapeutic Market Forecast Value (2024-2032)
4 Global mRNA Vaccine and Therapeutic Market Segmentation
4.1 Global mRNA Vaccine and Therapeutic Market Share by Type
4.1.1 Market Overview
4.1.2 Self-Amplifying mRNA Vaccines
4.1.3 Non-Amplifying mRNA Vaccines
4.2 Global mRNA Vaccine and Therapeutic Market Share by Route of Administration
4.2.1 Market Overview
4.2.2 Intravenous
4.2.3 Intramuscular
4.2.4 Intranasal
4.2.5 Others
4.3 Global mRNA Vaccine and Therapeutic Market Share by Therapeutic Area
4.3.1 Market Overview
4.3.2 Infectious Diseases
4.3.3 Oncological Disorders
4.3.4 Other Disorders
5 Global Market Dynamics
5.1 Market Drivers and Constraints
5.2 Porter's Five Forces Analysis
5.3 PESTEL Analysis
5.4 Industry Events, Initiatives, and Trends
5.5 Value Chain Analysis
6 Global mRNA Cancer Therapeutics Patent Landscape Analysis
6.1 Patent Distribution by Publication Year
6.2 Patent Distribution by Application Year
6.3 Patent Distribution by Priority Year
6.4 Analysis by Type of Patent
6.5 Analysis by Legal Status
6.6 Analysis by Patent Jurisdiction
6.7 Analysis by Patent Age
6.8 Analysis by Cooperative Patent Classification (CPC) Codes
6.9 Average Time to Publish a Patent
6.10 Analysis by Type of Entity (Academic and Non-Academic)
6.11 Analysis by Top Applicants
6.12 Analysis by Top Inventors
7 Global mRNA Cancer Therapeutics Patent Analysis by Technology
7.1 Total Patents by Top Technologies
7.2 Time Evolution of Patents by Technology
7.3 Emerging Technologies
7.4 Patent Segmentation, By Carrier
7.5 Patent Segmentation, By Route of Administration
7.6 Patent Segmentation, By Delivery Route
8 Patent Valuation Analysis
8.1 Assessment Methodology
8.2 High Value Patents
8.3 Medium Value Patents
8.4 Low Value Patents
9 Global mRNA Cancer Therapeutics - Top 10 Players Patent Analysis
9.1 Top 10 Entities by Number of Patents
9.2 Analysis by Publication Year
9.3 Analysis by Application Year
9.4 Analysis by Priority Year
9.5 Analysis by Type of Patent
9.6 Analysis by Jurisdiction
9.7 Analysis by Cooperative Patent Classification (CPC) Codes
9.8 Analysis by Source of Innovation
9.9 Analysis by Forward and Backward Citations
9.10 Analysis by Legal Status
9.11 Analysis by Patent Age
9.12 Analysis by Key Inventors
9.13 Entity Dynamics
10 Patent Profile of Key Players
10.1 Pfizer, Inc.
10.1.1 Product Portfolio
10.1.2 Patent Portfolio by Patent Families
10.1.3 Time Evolution of Patents
10.1.4 Geographical Patent Coverage
10.1.5 Patent Analysis by Technology
10.1.6 Patent News and Developments
10.1.7 Financial Analysis
10.1.8 SWOT Analysis
10.2 Modernatx Inc
10.3 Novartis AG
10.4 Genentech Inc.
10.5 Immatics Biotechnologies GmbH

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• mRNA Cancer Therapeutics Patent Landscape Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN11032025004107003653ID1109302381